FDA Approves Promega OncoMate® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA® in Combination with LENVIMA® In Advanced Endometrial Carcinoma
Promega MSI technology will aid in the identification of patients with microsatellite stable (MSS) endometrial carcinoma MADISON, Wis. — The U.S. Food and Drug Administration (FDA) has approved the Promega OncoMate® MSI Dx Analysis System as a companion diagn
(Financial Post, 2025-11-11T12:04:12Z)